GlassScriptPhysician profile
Manav Jasrotia
NPI 1801993910
$10,482.39
in general payments reported to CMS, 2019-2025
54 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $1,638 · 2021: $1,802 · 2022: $1,430 · 2023: $799 · 2024: $1,948 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,975 · Long Term Medical Supply Or Device Loan: $49.95 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,974.91 |
| Long Term Medical Supply Or Device Loan | $49.95 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,693.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,186.28 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,120.46 | 2019-2025 | Trelegy Ellipta, Shingrix, Nucala |
| Abbott Laboratories | $775.92 | 2019-2025 | Amplatzer Talisman, Freestyle Libre 3, Freestyle Insulinx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $655.47 | 2019-2025 | Jardiance, Synjardy, Jascayd |
| Pfizer INC. | $653.81 | 2019-2025 | |
| Astellas Pharma US INC | $460.94 | 2019-2025 | Veozah |
| Lilly USA, LLC | $363.01 | 2020-2025 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $357.53 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $304.35 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $289.23 | 2019-2025 | |
| Boston Scientific Corporation | $228.28 | 2021-2025 | Axonics, Bodyguardian, Watchman Flx |
| Merck Sharp & Dohme LLC | $219.28 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $182.36 | 2019-2024 | |
| Amarin Pharma, INC. | $173.80 | 2019-2022 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $147.35 | 2023-2025 | Korlym |
| Dexcom, INC. | $120.58 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $120.49 | 2021-2025 | |
| Biosense Webster, INC. | $103.05 | 2024 | Na |
| Amgen INC. | $102.37 | 2021-2024 | Repatha, Otezla |
| Medtronic, INC. | $100.47 | 2021-2025 | Symplicity G3, Linq II |
| Exact Sciences Corporation | $98.71 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $82.61 | 2020-2023 | Nexletol |
| Eisai INC. | $73.30 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.80 | 2024-2025 | Xifaxan, Trulance |
| Inspire Medical Systems, INC. | $58.67 | 2023-2024 | Inspire |
| Alexion Pharmaceuticals, INC. | $57.76 | 2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $52.64 | 2020-2021 | |
| Zyla Life Sciences, INC. | $45.49 | 2019 | |
| Sunovion Pharmaceuticals INC. | $44.48 | 2020 | |
| Currax Pharmaceuticals LLC | $40.39 | 2023 | Nexletol, Contrave, Onzetra Xsail |
| Nabriva Therapeutics, Plc | $38.97 | 2020-2021 | |
| Lundbeck LLC | $35.24 | 2024-2025 | Rexulti |
| Cequr Corporation | $34.53 | 2023-2024 | Cequr Simplicity |
| Sanofi Pasteur INC. | $29.43 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.56 | 2022 | |
| Alfasigma USA, INC. | $28.29 | 2020 | |
| Allergan, INC. | $25.72 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $23.72 | 2024 | Keveyis |
| Radius Health, INC. | $23.59 | 2019 | |
| Biogen, INC. | $22.46 | 2024 | Spinraza |
| Idorsia Pharmaceuticals US INC | $20.93 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.77 | 2019 | |
| Edwards Lifesciences Corporation | $20.27 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Takeda Pharmaceuticals U.S.A., INC. | $18.12 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.46 | 2025 | Caplyta |
| Verona Pharma, INC. | $17.33 | 2025 | Ohtuvayre |
| Ge Healthcare | $17.09 | 2019 | |
| Medtronic USA, INC. | $16.53 | 2019 | |
| Echosens North America, INC. | $16.39 | 2025 | Fibroscan |
| Ironwood Pharmaceuticals, INC | $16.29 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.53 | 2025 | Zoryve |
| Medtronic Vascular, INC. | $12.48 | 2019 | |
| Lucid Diagnostics INC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manav Jasrotia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.